Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

In this final analysis of the phase 3 ATALANTE/ENGOT-ov29 trial, researchers evaluated 5-year OS outcomes with and without the addition of atezolizumab to standard care.

The TROG 08.03 RAVES randomized controlled trial substudy examined quality of life after post-prostatectomy radiation therapy.

(HealthDay News) — Remote patient-reported outcome (PRO) monitoring may improve cancer care for underserved patients, according to a study recently published in JCO Oncology Practice.

This study evaluates public awareness of the link between human papillomavirus (HPV) and cervical cancer and examines the various factors that influence this knowledge among adults in the United ...

For this nationally representative survey, researchers aimed to determine how many US workers feel locked into their jobs to maintain health insurance, as well as factors that contribute to this job ...

The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

AYA cancer patients with sarcoma may not know resources, including palliative care, are available, and may resist them when ...

Investigators examined the effect of postpartum status on the 21-gene Oncotype DX Recurrence Score in women with hormone ...

Ashwin Kishtagari, MBBS, is Assistant Professor of Medicine in the division of hematology and oncology at Vanderbilt ...

The preferred management of patients with recurrent platinum-sensitive ovarian cancer (PSOC) is platinum-based doublet therapy with selective ...

Investigators pooled data from 4 trials to evaluate risk for recurrence in patients with intermediate risk non-muscle-invasive bladder cancer.